JP2020515582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515582A5 JP2020515582A5 JP2019553244A JP2019553244A JP2020515582A5 JP 2020515582 A5 JP2020515582 A5 JP 2020515582A5 JP 2019553244 A JP2019553244 A JP 2019553244A JP 2019553244 A JP2019553244 A JP 2019553244A JP 2020515582 A5 JP2020515582 A5 JP 2020515582A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- cancer
- use according
- related macrophages
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 49
- 210000002540 macrophage Anatomy 0.000 claims 24
- 201000011510 cancer Diseases 0.000 claims 12
- 241001465754 Metazoa Species 0.000 claims 9
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 6
- 102100022338 Integrin alpha-M Human genes 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 102000003814 Interleukin-10 Human genes 0.000 claims 3
- 108090000174 Interleukin-10 Proteins 0.000 claims 3
- 101100260702 Mus musculus Tinagl1 gene Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 101150088826 arg1 gene Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 239000006201 parenteral dosage form Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 210000002165 glioblast Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000002713 kidney leiomyosarcoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314688P | 2016-03-29 | 2016-03-29 | |
| US201662323282P | 2016-04-15 | 2016-04-15 | |
| US201662396409P | 2016-09-19 | 2016-09-19 | |
| USPCT/US2017/024770 | 2017-03-29 | ||
| PCT/US2017/024770 WO2017172930A1 (en) | 2016-03-29 | 2017-03-29 | Pbd conjugates for treating diseases |
| PCT/US2017/051662 WO2018182776A1 (en) | 2016-03-29 | 2017-09-14 | Folate conjugate for use in targeting tumor associated macrophages |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020515582A JP2020515582A (ja) | 2020-05-28 |
| JP2020515582A5 true JP2020515582A5 (enExample) | 2020-10-22 |
Family
ID=59965167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553244A Pending JP2020515582A (ja) | 2016-03-29 | 2017-09-14 | 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20200323991A1 (enExample) |
| JP (1) | JP2020515582A (enExample) |
| WO (1) | WO2017172930A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3268046A4 (en) | 2015-03-13 | 2018-11-21 | Endocyte, Inc. | Conjugates for treating diseases |
| CN110678204A (zh) * | 2016-03-29 | 2020-01-10 | 恩多塞特公司 | 用于靶向肿瘤相关巨噬细胞的叶酸缀合物 |
| WO2018031662A1 (en) * | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| WO2019104289A1 (en) * | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| CN109824622B (zh) * | 2019-02-27 | 2022-12-30 | 中国科学技术大学 | 一类细胞内形成纳米结构杀死癌细胞的前体药物及其制法 |
| CN120535564B (zh) * | 2025-07-24 | 2025-09-23 | 杭州诺泰诺和生物医药科技有限公司 | 一种含有Sar linker的多肽的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG185592A1 (en) * | 2010-05-19 | 2012-12-28 | Endocyte Inc | Improved process for a folate-targeted agent |
| EP2675479B1 (en) * | 2011-02-15 | 2016-01-13 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| US9662402B2 (en) * | 2012-10-16 | 2017-05-30 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
| CN110627797A (zh) * | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| PE20170935A1 (es) * | 2014-09-12 | 2017-07-13 | Genentech Inc | Anticuerpos anti-her2 e inmunoconjugados |
| CA2968837A1 (en) * | 2014-11-25 | 2016-06-02 | Endocyte, Inc. | Methods of treating cancer by targeting tumor-associated macrophages |
| EP3268046A4 (en) * | 2015-03-13 | 2018-11-21 | Endocyte, Inc. | Conjugates for treating diseases |
-
2017
- 2017-03-29 US US16/088,986 patent/US20200323991A1/en not_active Abandoned
- 2017-03-29 WO PCT/US2017/024770 patent/WO2017172930A1/en not_active Ceased
- 2017-09-14 JP JP2019553244A patent/JP2020515582A/ja active Pending
- 2017-09-14 US US16/498,071 patent/US20200038514A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515582A5 (enExample) | ||
| Leon et al. | Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways | |
| Kota et al. | Pancreatic cancer: Stroma and its current and emerging targeted therapies | |
| Mitra et al. | Novel delivery approaches for cancer therapeutics | |
| Lozada-Delgado et al. | RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials | |
| ES2548253T3 (es) | Métodos para el tratamiento de tumores sólidos | |
| Nazir et al. | Nanomaterials in combating cancer: therapeutic applications and developments | |
| JP2015520753A5 (enExample) | ||
| JP2016538257A5 (enExample) | ||
| Yin et al. | A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy | |
| ES2471452T3 (es) | Uso de 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4-trifluorometil-piridin-2-ilamina para el tratamiento de carcinoma de pulmón de células no pequeñas con resistencia adquirida a los moduladores del receptor del factor de crecimiento epid�rmico (EGFR). | |
| PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| JP2011510056A5 (enExample) | ||
| JP2016513661A5 (enExample) | ||
| JP2014512354A5 (enExample) | ||
| JP2014509659A5 (enExample) | ||
| NZ563774A (en) | Inhibitors of VEGF receptor and HGF receptor signaling | |
| EP3148336A1 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| JP2009536156A5 (enExample) | ||
| JP2017514806A5 (enExample) | ||
| JP2018062523A5 (enExample) | ||
| ES2401822T3 (es) | Utilización de imidazoquinolinas para el tratamiento de enfermedades dependientes de EGFR o enfermedades que han adquirido resistencia a agentes que tienen como objetivo mienbros de la familia de EGFR | |
| ES2826558T3 (es) | Nuevas terapias para el cáncer | |
| JP2016224056A5 (enExample) | ||
| JP2016504325A5 (enExample) |